Participants were not smoking or drinking and were not taking vitamin therapy.
Written informed consent was obtained from all participants whose blood groups had been worked before, and the study protocol was approved by the Local Ethics Committee of Harran University.
| Blood collection and platelet indices measurement
Venous blood samples were collected from each participant after at least 8 hours of overnight fasting. The blood samples were taken in tubes containing ethylenediaminetetraacetic acid. To prevent in vitro platelet activation, all the measurements were performed immediately after the blood collection. Platelet count (PLT), MPV, PDW, and plateletcrit (PCT) were studied by an auto-analyzer (Abbott Cell-Dyn Ruby Hematology Analyzer, USA). Blood groups were determined by the gel column blood typing method using agglutination techniques.
| Statistical analysis
Statistical analyses were conducted with SPSS for Windows version 23.0 software (IBM SPSS Inc, Chicago, IL, USA). The Shapiro-Wilk test was used to evaluate the normal distribution of the data, and all the data were found to be normally distributed. Numerical variables were presented as mean ± standard deviation, and categorical variables were stated as number (n) and percentage (%). A two-sample comparison of numerical variables was conducted by an unpaired Student's t test, and multiple comparisons of numerical variables were conducted by analysis of variance (two-way ANOVA, Bonferroni's post hoc test).
The chi-square test was also used to compare categorical variables. The confidence interval was accepted as 95% throughout the analyses. A two-tailed P value of <0.05 was considered statistically significant.
| RE SULTS
The demographic characteristics of the enrolled subjects are summarized in Table 1 . There were no significant differences with respect to age, gender, BMI, or Rh factors among ABO blood group subjects (P > 0.05 for each).
The comparison of alterations in platelet indices among ABO blood group subjects is presented in Table 2 and in Figures 1 and 2 . MPV was found to be significantly lower in both O and A blood group subjects than in B and AB blood group subjects (P < 0.05 for each).
Additionally, PDW was detected to be considerably lower in O and A blood group subjects than in B blood group subjects (P < 0.006 and P < 0.019, respectively). However, no considerable differences with respect to PLT and PCT among ABO blood group subjects were detected (P > 0.05 for each).
The platelet indices of O blood group subjects and non-O blood groups are compared in Table 3 and Figure 3 . MPV values were found to be considerably lower in O blood group subjects than in non-O blood group subjects (P = 0.008). However, there were no significant differences between O blood group subjects and non-O blood group subjects in terms of PLT, PCT, or PDW (P > 0.05).
| D ISCUSS I ON
Although there is a confirmed association between ABO blood groups and CVDs [1] [2] [3] [4] and between platelet indices and thromboembolic and atherosclerotic CVD, 11, [14] [15] [16] to the best of our knowledge, there is no study that addresses the relationship between platelet indices and CVDs in healthy adults. Hence, we aimed to investigate whether MPV and PDW, two important indicators of platelet activity, had relationships with ABO blood groups in healthy adult subjects. Studies have elucidated that non-O blood group subjects have a higher coronary heart disease risk 19 and increased atherosclerotic cardiovascular mortality 20 compared with O blood group subjects.
It has also been detected that there is a lower incidence of coronary heart disease in O blood group subjects as compared with A blood group subjects in Western countries. 2, 21 Similarly, some authors have argued that there is a high correlation between MPV and CVDs. 11, 15, 22 Besides, this biomarker could be an early predictive factor for cardiac diseases and could give information for prognosis of the pathology. 16, 23, 24 Also, Cetin et al found a relationship between MPV and thrombolysis failure in patients with ST-segment elevation MI. 25 In relation to these studies, we found that O blood group subjects have considerably decreased MPV levels than do B
and AB blood group subjects (P = 0.004 and P = 0.001, respectively).
Moreover, in this study, MPV levels in O blood group subjects were significantly lower than MPV levels in non-O blood group subjects (P = 0.008). However, several other studies have reported that there is no relationship between MPV and CAD. 11, 26 Similarly, Karabuva et al presented that ABO blood groups were not associated with the presence of atherosclerotic CAD. Similarly, no relationship was observed between ABO groups and Behçet's disease. 29 Beckman et al 30 stated that A-factor of ABO blood groups was found increased in the patients with psoriasis.
Xie et al 31 declared that non-O blood group was associated with decreased risk of skin cancers. Beside this, there was a significant relationship between non-O blood groups and non-melanoma cancers.
31
A systematic review and meta-analysis study conducted by Chen et al 4 indicates that risk factors for CAD are high in both A blood group subjects and non-O blood group subjects. In addition, other studies have suggested that the A blood group is an independent risk factor for coronary atherosclerosis and ischemic CVD. 2, 32, 33 In contrast to previous studies, MPV, a useful prognostic marker in patients with CAD and venous thrombosis, was found to be significantly lower in A blood group subjects than in B and AB blood group subjects (P = 0.024 and P = 0.007, respectively).
We also observed that PDW, an indicator of prothrombotic status, 34 was significantly higher in B blood group subjects than in A and O blood group subjects (P = 0.019 and P = 0.006, respectively). In accordance with our study, many investigations have shown that PDW was significantly higher in subjects with CAD and thrombolysis failure. 25, [35] [36] [37] However, other studies have reported that there is no relationship between PDW and the extent of CAD. Ali Ziya Karakilcik https://orcid.org/0000-0002-6561-6346
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